PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
0.79%
Revenue growth of 0.79% vs. zero growth in Drug Manufacturers - Specialty & Generic. Walter Schloss might still want to see if it can translate into profits.
66.19%
Gross profit growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.34%. Joel Greenblatt would check if cost advantages or brand equity drive this surge.
131.77%
EBIT growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 14.04%. Joel Greenblatt would examine whether a unique competitive edge supports this outperformance.
131.77%
Operating income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 19.02%. Joel Greenblatt would see if unique processes drive exceptional profitability.
94.53%
Net income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 24.77%. Joel Greenblatt would check if brand strength or cost advantages fuel this outperformance.
94.63%
EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 26.24%. Joel Greenblatt would confirm if consistent earnings expansion underpins these gains.
94.63%
Diluted EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 26.70%. Joel Greenblatt would confirm if strong net income growth or buybacks drive outperformance.
0.77%
Share growth above Drug Manufacturers - Specialty & Generic median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
0.77%
Diluted share growth above 2x Drug Manufacturers - Specialty & Generic median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
-1372.80%
Negative OCF growth while Drug Manufacturers - Specialty & Generic median is -2.79%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-213.23%
Negative FCF growth while Drug Manufacturers - Specialty & Generic median is -1.43%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
2699.78%
5Y revenue/share growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.31%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
995.84%
3Y revenue/share growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.81%. Joel Greenblatt might see a short-term competitive advantage at play.
-10471.05%
Negative 10Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-1899.91%
Negative 5Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-745.55%
Negative 3Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
-322.72%
Negative 10Y net income/share CAGR vs. Drug Manufacturers - Specialty & Generic median of 30.24%. Seth Klarman might see a fundamental problem if peers maintain growth.
-96.58%
Negative 5Y CAGR while Drug Manufacturers - Specialty & Generic median is 19.08%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-115.70%
Negative 3Y CAGR while Drug Manufacturers - Specialty & Generic median is 0.20%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
5649.27%
Equity/share CAGR exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 38.22% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
2476.44%
5Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 32.17%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
188.63%
3Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 18.33%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
53.57%
AR growth of 53.57% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
37.86%
Inventory growth far above Drug Manufacturers - Specialty & Generic median. Jim Chanos suspects major issues in demand forecasting or potential obsolescence risk.
5.69%
Asset growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.46%. Joel Greenblatt confirms strong expansions matched by adequate returns on those assets.
5.89%
BV/share growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median. Joel Greenblatt checks if consistent ROE or undervalued buybacks fuel this advantage.
8.09%
Slightly rising debt while Drug Manufacturers - Specialty & Generic median is deleveraging. Peter Lynch wonders if the firm lags behind peers in risk control or invests in more expansions.
-72.57%
R&D dropping while Drug Manufacturers - Specialty & Generic median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
8.97%
SG&A growth of 8.97% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.